(Q37076331)

18 August 2017

1 reference

title

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing (English)

1 reference

18 August 2017

0 references

1 reference

1 reference

Marina Kacevska

1

1 reference

18 August 2017

Graham R Robertson

series ordinal

2

1 reference

18 August 2017

Stephen J Clarke

series ordinal

3

1 reference

18 August 2017

Christopher Liddle

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Drug Metabolism & Toxicology

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

137-149

1 reference

CYP3A gene expression in human gut epithelium

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Cytochrome P-450 3A4: regulation and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Predicting inductive drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Cytochrome P450 and anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Pharmacogenetics of irinotecan metabolism and transport: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Cytochrome P450 pharmacogenetics and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The erythromycin breath test for the prediction of drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Cytochrome P450 and liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Regulation of drug-metabolizing enzymes and transporters in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Regulation of drug transporters during infection and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

A cytokine-mediated link between innate immunity, inflammation, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The adaptive immunologic microenvironment in colorectal cancer: a novel perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Nuclear receptors and drug disposition gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

CAR: detailing new models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Transcriptional regulation and expression of CYP3A4 in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Humanized xenobiotic response in mice expressing nuclear receptor SXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Significance of interleukin-6 (IL-6) in breast cancer (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Cytokines in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Circulating biomarkers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Interleukin-6 polymorphism is associated with more aggressive prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.137

21 January 2018

Identifiers

DOI

10.1517/17425255.4.2.137

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b2ckpcickbhatinby7eulalycy

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_b2ckpcickbhatinby7eulalycy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b2ckpcickbhatinby7eulalycy

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/b2ckpcickbhatinby7eulalycy

1 reference